Ukr.Biochem.J. 2017; Volume 89, Issue 6, Nov-Dec, pp. 3-12

doi: https://doi.org/10.15407/ubj89.06.003

Synthesis and investigation of the derivatives of amidinohydrazonelated aromatic compounds as furin inhibitors

T. V. Osadchuk1, A. V. Semyroz1, O. V. Shybyryn1, V. K. Kibirev1,2

1Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Kyiv;
2Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: osadchuk@bpci.kiev.ua

The proprotein convertase furin plays a crucial role in a variety of pathogenic processes such as cancer, bacterial and viral diseases, neurodegenerative disorders and diabetes. Thus, furin inhibitors are promi­sing therapeutics for the treatment of many diseases. In this study we synthesized some new non-peptide of furin inhibitors, with positively charged amidinohydrazone groups present in ortho-, meta– or para-positions in the benzene rings relative to the linker. From the results of biological testing it followed that the position of amidinohydrazone groups in aromatic rings was significant for the manifestation of antifurin activity. The replacement of linkers containing a propoxy group by a “bridge” with a benzene ring was found to cause an increase in the inhibitory effect of the compounds. The effect of synthesized bisamidinohydrazones on furin also depended on the substitution of the hydrogen atom in the amidinohydrazone group by the methyl group. These compounds were shown to block the enzyme activity mainly by the mechanism of mixed inhibition, and their Ki values were at the micromolar level.

Keywords: , , ,


References:

  1. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem. 1992 Aug 15;267(23):16396-402. PubMed
  2. Hosaka M, Nagahama M, Kim WS, Watanabe T, Hatsuzawa K, Ikemizu J, Murakami K, Nakayama K. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem. 1991 Jul 5;266(19):12127-30. PubMed
  3. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66. PubMed, PubMedCentral, CrossRef
  4. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012 May;11(5):367-83. PubMed, CrossRef
  5. Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med. 2011 Dec 29;365(26):2507-18. PubMed, CrossRef
  6. Solovyeva NI, Gureeva TA, Timoshenko OS, Moskvitina TA, Kugaevskaya EV. Furin as proprotein convertase and its role in normaland pathological biological processes. Biomed Khim. 2016 Nov;62(6):609-621. (In Russian). PubMed, CrossRef
  7. Basak A. Inhibitors of proprotein convertases. J Mol Med (Berl). 2005 Nov;83(11):844-55. PubMed, CrossRef
  8. De UC, Mishra P, Pal PR, Dinda B, Basak A. Non-peptide inhibitors of proprotein convertases subtilisin kexins (PCSKs). An overall review of existing and new data (ed. M.Khatib). Colloq Ser Protein Activation Cancer. 2012;1(3):1-76. CrossRef
  9. Kibirev VK, Osadchuk TV. Structure and properties of proprotein convertase inhibitors. Ukr Biokhim Zhurn. 2012 Mar-Apr;84(2):5-29. (In Russian). PubMed
  10. Couture F, Kwiatkowska A, Dory YL, Day R. Therapeutic uses of furin and its inhibitors: a patent review. Expert Opin Ther Pat. 2015 Apr;25(4):379-96. PubMed, CrossRef
  11. Osadchuk TV, Shybyryn OV, Kibirev VK. Chemical structure and properties of low-molecular furin inhibitors. Ukr Biochem J. 2016;88(6):5-25. CrossRef
  12. Komiyama T, Coppola JM, Larsen MJ, van Dort ME, Ross BD, Day R, Rehemtulla A, Fuller RS. Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem. 2009 Jun 5;284(23):15729-38.  PubMed, PubMedCentral, CrossRef
  13. Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bakowsky U, Day R, Garten W, Steinmetzer T. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem. 2012 Jun 22;287(26):21992-2003. PubMed, PubMedCentral, CrossRef
  14. Hardes K, Becker GL, Lu Y, Dahms SO, Köhler S, Beyer W, Sandvig K, Yamamoto H, Lindberg I, Walz L, von Messling V7 Than ME, Garten W, Steinmetzer T. Novel furin inhibitors with potent anti-infectious activity. Chem Med Chem. 2015 Jul;10(7):1218-31.  PubMed, CrossRef
  15. Fittler H, Depp A, Avrutina O, Dahms SO, Than ME, Empting M, Kolmar H. Engineering a Constrained Peptidic Scaffold towards Potent and Selective Furin Inhibitors. ChemBioChem. 2015 Nov;16(17):2441-4.  PubMed, CrossRef
  16. Sielaff F, Than ME, Bevec D, Lindberg I, Steinmetzer T. New furin inhibitors based on weakly basic amidinohydrazones. Bioorg Med Chem Lett. 2011 Jan 15;21(2):836-40.  PubMed, PubMedCentral, CrossRef
  17. Kibirev VK, Osadchuk TV, Kozachenko AP, Vadziuk OB, Brovarets VS. Non-peptide furin inhibitors based on amidinohydrazones of diarylaldehydes. Ukr Biokhim Zhurn. 2013 Jan-Feb;85(1):22-32. (In Russian). PubMed
  18. Kibirev VK, Osadchuk TV, Kozachenko OP, Kholodovych V, Fedoryak D, Brovarets VS. Synthesis, biological evaluation and docking of novel bisamidinohydrazones as non-peptide inhibitors of furin. Ukr Biochem J. 2015 Jan-Feb;87(1):55-63. PubMed, CrossRef
  19. Meiser W., Domagk G. Di-guanyl hydrazones. US Patent  2815377, 1957. 3 dec 1957.
  20. Borges MN, Messeder JC, Figueroa-Villar JD. Synthesis, anti-Trypanosoma cruzi activity and micelle interaction studies of bisguanylhydrazones analogous to pentamidine. Eur J Med Chem. 2004 Nov;39(11):925-9.  PubMed, CrossRef
  21. Mondal R, Mandal TK, Mallik AK. Simple synthesis of a new family of 22- to 28-membered macrocycles containing two chalcone moieties. Arkivoc. 2012;2012(9): 95-110.  CrossRef
  22. Kamal A, Shaheer Malik M, Bajee S, Azeeza S, Faazil S, Ramakrishna S, Naidu VG, Vishnuwardhan MV. Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones. Eur J Med Chem. 2011 Aug;46(8):3274-81.  PubMed, CrossRef
  23. Basílio N, Garnier T, Avó J, Danel M, Chassaing S, Pina F. Synthesis and multistate characterization of bis-flavylium dications – symmetric resorcinol- and phloroglucinol-type derivatives as stochastic systems. RSC Adv. 2016;6(74):69698-69707.  CrossRef
  24. Tassi M, Bartollini E, Adriaensens P, Bianchi L, Barkakaty B, Carleer R, Chen J, Hensley DK, Marrocchi A, Vaccaro L. Synthesis, characterization and catalytic activity of novel large network polystyrene-immobilized organic bases. RSC Adv. 2015;5(130):107200-107208. CrossRef
  25. McMillan FH. Diaryloxyalkane derivatives. Some miscellaneous diphenoxypropanes. J Am Chem Soc. 1952;74(20):5229-5230.  CrossRef
  26. Singh C, Verma VP, Naikade NK, Singh AS, Hassam M, Puri SK. Novel bis- and tris-1,2,4-trioxanes: synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice. J Med Chem. 2008 Dec 11;51(23):7581-92.  PubMed, CrossRef
  27. Ramos-Molina B, Lick AN, Blanco EH, Posada-Salgado JA, Martinez-Mayorga K, Johnson AT, Jiao GS, Lindberg I. Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays. Biochem Pharmacol. 2015 Jul 15;96(2):107-18.  PubMed,PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.